)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Beam Therapeutics
Beam Therapeutics (BEAM) investor relations material
Beam Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Announced expansion of the liver-targeted portfolio with BEAM-304, a new base editing program for PKU, targeting the two most common mutations and aiming to address a majority of PKU patients over time, with IND filing anticipated in 2026.
Provided updates on the anticipated commercialization of risto-cel for sickle cell disease, supported by a new $500M strategic financing agreement with Sixth Street.
Highlighted the modular, scalable nature of the base editing platform, enabling efficient development of therapies for multiple genetic diseases.
Emphasized strong financial position with $1.25B in cash and marketable securities at year-end 2025 and a projected runway into mid-2029.
Updated Phase 1/2 data and pivotal development for BEAM-302 in alpha-1 antitrypsin deficiency expected in Q1 2026.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $1.25B as of December 31, 2025, up from $850.7M at year-end 2024.
Secured up to $500M in long-term, non-dilutive capital from Sixth Street, with $100M funded at close and additional tranches tied to risto-cel milestones.
R&D expenses were $99.3M for Q4 2025 and $409.6M for the full year, compared to $101.4M and $367.6M in 2024.
G&A expenses were $32.3M for Q4 2025 and $113.8M for the year, up from $28.7M and $111.5M in 2024.
Net income for Q4 2025 was $244.3M ($2.37 per basic share), while the full year saw a net loss of $80.0M ($0.81 per share).
Outlook and guidance
IND filing for BEAM-304 in PKU expected in 2026, with initial focus on R408W mutation and plans to expand to additional mutations.
BEAM-302 pivotal development update and risto-cel BLA submission anticipated by year-end 2026.
Continued advancement of pipeline, including BEAM-301 data in GSD Ia and BEAM-103 healthy volunteer study.
Cash runway expected to fund operations into mid-2029, covering major clinical and commercial milestones.
Explain BEAM-304's multi-editor strategy
What are conditions for Sixth Street funding?
What is BEAM-302's accelerated approval path?
How will new PKU variants be added to trials?
Risto-cel's manufacturing advantage vs. competitors?
What AAT levels are targeted for BEAM-302 pivotal?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Beam Therapeutics earnings date
Q1 20266 May, 2026
Beam Therapeutics
Next Beam Therapeutics earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Beam Therapeutics Inc is a biotechnology company focused on the development of precision genetic medicines using base editing technology. The company’s approach aims to correct genetic mutations at the single-base level to treat various diseases, including genetic disorders and cancers. It conducts research and development in-house and through collaborations. Beam Therapeutics Inc is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage